Piśmiennictwo:

1. [Khachadurian AK](http://www.ncbi.nlm.nih.gov/pubmed?term=Khachadurian%20AK%5BAuthor%5D&cauthor=true&cauthor_uid=4351242), [Uthman SM](http://www.ncbi.nlm.nih.gov/pubmed?term=Uthman%20SM%5BAuthor%5D&cauthor=true&cauthor_uid=4351242) Experiences with the homozygous cases of familial hypercholesterolemia. A report of 52 patients [Nutr Metab.](http://www.ncbi.nlm.nih.gov/pubmed/4351242) 1973;15(1):132-40
2. Broncel M. Aktualne kryteria rozpoznawania dyslipidemii. Docelowe stężenia lipidów w chorobach serca i naczyń Kardiologia Oparta na Faktach 2010; 1: 15–28
3. Aalst-Coben ES, Jansen AC, Tranch MW Diagnosis familial hypercholesterolemia the relevance of genetic testing Eur Heart J 2006; 27: 2240-6
4. Lewartowski B. PCSK9 – początek przełomu w zapobieganiu ileczeniu miażdżycy? Kardiologia Polska 2009; 67: 7
5. [Südhof TC](http://www.ncbi.nlm.nih.gov/pubmed?term=S%C3%BCdhof%20TC%5BAuthor%5D&cauthor=true&cauthor_uid=3611089), [Van der Westhuyzen DR](http://www.ncbi.nlm.nih.gov/pubmed?term=Van%20der%20Westhuyzen%20DR%5BAuthor%5D&cauthor=true&cauthor_uid=3611089), [Goldstein JL](http://www.ncbi.nlm.nih.gov/pubmed?term=Goldstein%20JL%5BAuthor%5D&cauthor=true&cauthor_uid=3611089) Three direct repeats and a TATA-like sequence are required for regulated expression of the human low density lipoprotein receptor gene [J Biol Chem.](http://www.ncbi.nlm.nih.gov/pubmed/3611089) 1987 Aug 5;262(22):10773-9.
6. [Mehta KD](http://www.ncbi.nlm.nih.gov/pubmed?term=Mehta%20KD%5BAuthor%5D&cauthor=true&cauthor_uid=8919878), [Chang R](http://www.ncbi.nlm.nih.gov/pubmed?term=Chang%20R%5BAuthor%5D&cauthor=true&cauthor_uid=8919878), [Norman J](http://www.ncbi.nlm.nih.gov/pubmed?term=Norman%20J%5BAuthor%5D&cauthor=true&cauthor_uid=8919878). Chiloscyllium plagiosum low-density lipoprotein receptor: evolutionary conservation of five different functional domains [J Mol Evol.](http://www.ncbi.nlm.nih.gov/pubmed/8919878) 1996 Feb;42(2):264-72
7. [Yang Y](http://www.ncbi.nlm.nih.gov/pubmed?term=Yang%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=11809850), [Ballatori N](http://www.ncbi.nlm.nih.gov/pubmed?term=Ballatori%20N%5BAuthor%5D&cauthor=true&cauthor_uid=11809850), [Smith HC](http://www.ncbi.nlm.nih.gov/pubmed?term=Smith%20HC%5BAuthor%5D&cauthor=true&cauthor_uid=11809850). Apolipoprotein B mRNA editing and the reduction in synthesis and secretion of the atherogenic risk factor, apolipoprotein B100 can be effectively targeted through TAT-mediated protein transduction [Mol Pharmacol.](http://www.ncbi.nlm.nih.gov/pubmed/11809850) 2002 Feb;61(2):269-76.
8. Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differetiation. *Proc Natl* *Acad Sci* USA 2003; 100: 928-33.
9. [Horton JD](http://www.ncbi.nlm.nih.gov/pubmed?term=Horton%20JD%5BAuthor%5D&cauthor=true&cauthor_uid=17215125), [Cohen JC](http://www.ncbi.nlm.nih.gov/pubmed?term=Cohen%20JC%5BAuthor%5D&cauthor=true&cauthor_uid=17215125), [Hobbs HH](http://www.ncbi.nlm.nih.gov/pubmed?term=Hobbs%20HH%5BAuthor%5D&cauthor=true&cauthor_uid=17215125) Molecular biology of PCSK9: its role in LDL metabolism [Trends Biochem Sci.](http://www.ncbi.nlm.nih.gov/pubmed/17215125) 2007 Feb;32(2):71-7. Epub 2007 Jan 9
10. Fisher TS, Lo Surdo P, Pandit S Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation *J Biol Chem* 2007; 282: 20502-12
11. Zaid A, Roubtsova A, Essalmani R Protein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology 2008; 48: 646-54
12. [Pandit S](http://www.ncbi.nlm.nih.gov/pubmed?term=Pandit%20S%5BAuthor%5D&cauthor=true&cauthor_uid=18354137), [Wisniewski D](http://www.ncbi.nlm.nih.gov/pubmed?term=Wisniewski%20D%5BAuthor%5D&cauthor=true&cauthor_uid=18354137), [Santoro JC](http://www.ncbi.nlm.nih.gov/pubmed?term=Santoro%20JC%5BAuthor%5D&cauthor=true&cauthor_uid=18354137) Functional analysis of sites within PCSK9 responsible for hypercholesterolemia [J Lipid Res.](http://www.ncbi.nlm.nih.gov/pubmed/18354137) 2008 Jun;49(6):1333-43
13. [Chan JC](https://ssl.wum.edu.pl/%2CDanaInfo%3D.awxyCrhhpHwvxL0wwPx6C%2Bpubmed?term=Chan%20JC%5BAuthor%5D&cauthor=true&cauthor_uid=19443683), [Piper DE](https://ssl.wum.edu.pl/%2CDanaInfo%3D.awxyCrhhpHwvxL0wwPx6C%2Bpubmed?term=Piper%20DE%5BAuthor%5D&cauthor=true&cauthor_uid=19443683), [Cao Q](https://ssl.wum.edu.pl/%2CDanaInfo%3D.awxyCrhhpHwvxL0wwPx6C%2Bpubmed?term=Cao%20Q%5BAuthor%5D&cauthor=true&cauthor_uid=19443683) A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates [Proc Natl Acad Sci U S A.](https://ssl.wum.edu.pl/pubmed/%2CDanaInfo%3D.awxyCrhhpHwvxL0wwPx6C%2B19443683) 2009 Jun 16;106(24):9820-5
14. [Koren MJ](https://ssl.wum.edu.pl/%2CDanaInfo%3D.awxyCrhhpHwvxL0wwPx6C%2Bpubmed?term=Koren%20MJ%5BAuthor%5D&cauthor=true&cauthor_uid=23141812), [Scott R](https://ssl.wum.edu.pl/%2CDanaInfo%3D.awxyCrhhpHwvxL0wwPx6C%2Bpubmed?term=Scott%20R%5BAuthor%5D&cauthor=true&cauthor_uid=23141812), [Kim JB](https://ssl.wum.edu.pl/%2CDanaInfo%3D.awxyCrhhpHwvxL0wwPx6C%2Bpubmed?term=Kim%20JB%5BAuthor%5D&cauthor=true&cauthor_uid=23141812), [Knusel B](https://ssl.wum.edu.pl/%2CDanaInfo%3D.awxyCrhhpHwvxL0wwPx6C%2Bpubmed?term=Knusel%20B%5BAuthor%5D&cauthor=true&cauthor_uid=23141812) Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study [Lancet.](https://ssl.wum.edu.pl/pubmed/%2CDanaInfo%3D.awxyCrhhpHwvxL0wwPx6C%2B23141812) 2012 Dec 8;380(9858):199
15. [McKenney JM](http://www.ncbi.nlm.nih.gov/pubmed?term=McKenney%20JM%5BAuthor%5D&cauthor=true&cauthor_uid=22463922), [Koren MJ](http://www.ncbi.nlm.nih.gov/pubmed?term=Koren%20MJ%5BAuthor%5D&cauthor=true&cauthor_uid=22463922), [Kereiakes DJ](http://www.ncbi.nlm.nih.gov/pubmed?term=Kereiakes%20DJ%5BAuthor%5D&cauthor=true&cauthor_uid=22463922) Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy [J Am Coll Cardiol.](http://www.ncbi.nlm.nih.gov/pubmed/22463922) 2012 Jun 19;59(25):2344-53
16. [Stein EA](http://www.ncbi.nlm.nih.gov/pubmed?term=Stein%20EA%5BAuthor%5D&cauthor=true&cauthor_uid=22435370), [Mellis S](http://www.ncbi.nlm.nih.gov/pubmed?term=Mellis%20S%5BAuthor%5D&cauthor=true&cauthor_uid=22435370), [Yancopoulos GD](http://www.ncbi.nlm.nih.gov/pubmed?term=Yancopoulos%20GD%5BAuthor%5D&cauthor=true&cauthor_uid=22435370) Effect of a monoclonal antibody to PCSK9 on LDL cholesterol [N Engl J Med.](http://www.ncbi.nlm.nih.gov/pubmed/22435370) 2012 Mar 22;366(12):1108-18
17. Sitniewska E, Gajewska H. Kinalska I. Terapia statynami jako cel redukcji ryzyka sercowo-naczyniowego u pacjentów z cukrzycą Przegląd Kardiodiabetologiczny 2009; 4 (3): 97–105
18. [Sullivan D](http://www.ncbi.nlm.nih.gov/pubmed?term=Sullivan%20D%5BAuthor%5D&cauthor=true&cauthor_uid=23128163), [Olsson AG](http://www.ncbi.nlm.nih.gov/pubmed?term=Olsson%20AG%5BAuthor%5D&cauthor=true&cauthor_uid=23128163), [Scott R](http://www.ncbi.nlm.nih.gov/pubmed?term=Scott%20R%5BAuthor%5D&cauthor=true&cauthor_uid=23128163) Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients: The GAUSS Randomized Trial Jama 2012 Nov 5:1-10
19. [Liang H](http://www.ncbi.nlm.nih.gov/pubmed?term=Liang%20H%5BAuthor%5D&cauthor=true&cauthor_uid=22019884), [Chaparro-Riggers J](http://www.ncbi.nlm.nih.gov/pubmed?term=Chaparro-Riggers%20J%5BAuthor%5D&cauthor=true&cauthor_uid=22019884), [Strop P](http://www.ncbi.nlm.nih.gov/pubmed?term=Strop%20P%5BAuthor%5D&cauthor=true&cauthor_uid=22019884) Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates [J Pharmacol Exp Ther.](http://www.ncbi.nlm.nih.gov/pubmed/22019884) 2012 Feb;340(2):228-36